Sandra G. Stoneman: Lawyer with Duane Morris LLP

Sandra G. Stoneman

Philadelphia,  PA  U.S.A.

Peer Rating

Client Rating

Printer Friendly VersionEmail this PageDownload to My Outlook ContactsAdd lawyer to My FavoritesCompare this lawyer to other lawyers in your favorites

Experience & Credentials

Practice Areas

  • Corporate Law
  • Venture Capital
  • Mergers and Acquisitions
  • Business Law and Finance
  • Licensing/Strategic Alliances
  • Commercial Contracts
  • Securities Law
Contact InfoTelephone: 215.979.1360
Fax: 215.689.4420
Law SchoolTemple University School of Law, J.D., magna cum laude, 1997
Admitted1997, Pennsylvania

Professional Activities

•PACT (Greater Philadelphia Alliance for Capital and Technologies)
- Board of Directors (2014-present)
- Member of MedTech Advisory Board (2015-present)
•IMPACT Capital Conference
- Member, Steering Committee (2011-present)
- Head, Entrepreneur Outreach Committee (2013-present)
•Alliance of Women Entrepreneurs-Programming Committee (2014-present)
•FESPP (Friends of Eastern State Penitentiary)
- Board of Directors (2012-present)
•Professional Women's Roundtable
- Member, Advisory Board (2009-present)
- Board of Directors (2002-2009)
•Epilepsy Foundation of Southeastern Pennsylvania
- Member, Board of Directors
•Graduate of Leadership, Inc.

BornBrooklyn, New York, June 19, 1972

Sandra G. Stoneman is co-head of the firm's Life Sciences Practice Group and serves on the firm's Diversity & Inclusion Committee. Ms. Stoneman concentrates her practice in the areas of general corporate, mergers and acquisitions, venture capital and private equity and securities law, representing entrepreneurs, emerging companies, public companies and investors. She also serves as outside general counsel to emerging healthcare and technology companies, representing them in various matters from formation through exit, including organization and structure matters, founder relationships, financing arrangements, strategic, licensing and partnering transactions, clinical trial and other research agreements and commercial and operational arrangements. Additionally, Ms. Stoneman advises management and boards of directors on corporate governance matters.

Ms. Stoneman is an adjunct professor at Temple Law School, teaching a Practicum on entrepreneur legal support.

Ms. Stoneman is a 1997 magna cum laude graduate of Temple University School of Law, where she was an articles editor for the Temple Law Review, and is a summa cum laude graduate of the State University of New York at Binghamton.

Honors & Awards

•Named one of Pennsylvania's Lawyers on the Fast Track by The Legal Intelligencer, August 2008
•Named a Super Lawyer Rising Star by the publishers of Law and Politics magazine, 2005-2007

Selected Speaking Engagements

•Moderator, Big Data: What are the Opportunities in Healthcare?, Greater Philadelphia Alliance for Capital and Technologies (November 2014)
•Speaker, Stakeholder Agreements and Choice of Entity, Temple University Blackstone Launchpad Program (October 2014)
•Panelist, Pharmaceutical Consulting Consortium International Meeting, (February 2014)
•Frequent lecturer at The Women's Business Development Center JumpStart panel programs (2010-present)
•Panelist, Power of Persuasion event hosted by Entrepreneurs' Forum, (May 2008)
•Speaker, Choice of Entity, Wharton Venture Initiation Program Presentation, (February 2008)
•Panelist, How to Become Fundable, lunch panel discussion at New Jersey Technology Council Venture Fair, (March 2006)

Selected Publications

• Celebrating Five Years Stronger: A Few Words from PACT Leaders, imPACT Times, June 2015
•Co-author, SEC Adopts 'Regulation A+' Rules, Duane Morris Alert, April 10, 2015
• Judicial and Congressional Back-Door Methods That Limit the Effect of Roe v. Wade: There is No Choice if There is No Access, Temple Law Review (1997)

Reported CasesRepresentative Matters: Represented an immunotherapy company in its $5 million Series A Preferred Stock financing.; Represented a medical device company in its $3 million Series C Preferred Stock financing.; Represented a venture firm in its investment in a digital sales platform company in its $2.5 million Series A Preferred Stock financing.; Represented MELA Sciences, Inc. (NASDAQ:MELA) in its purchase of the XTRAC and VTRAC dermatology business from PhotoMedex, Inc. for $42.5 million in cash and the assumption of certain business-related liabilities and the related financing with institutional investors consisting of a private placement of $42.5 million aggregate principal amount of senior secured notes and convertible debentures and warrants to purchase 3.0 million shares of common stock.; Represented Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, in its $38.9 million Series B Preferred Stock financing to accelerate the development and FDA approval of the company's endovascular dissection repair technology.; Represent BioBots, which develops and sells desktop bioprinters that build 3D living tissues out of human cells, in its financings and general corporate matters.; Represented Apogee Biotechnology in the exclusive worldwide license to Redhill Biopharma of Apogee's lead compounds and related intellectual property rights.; Represented Marinus Pharmaceuticals, Inc., a biopharmaceutical company developing neuropsychiatric therapeutics, in its $46 million initial public offering of common stock, and transitioning from a venture-financed company to a public company. Also represented Marinus in its $21 million Series C Preferred Stock financing from U.S. venture capital firm Domain Associates, LLC, Russian state-owned investment fund RusnanoMedInvest, and co-investors Canaan Partners, Sofinnova Ventures and Foundation Medical Partners.; Counsel to Celator Pharmaceuticals, Inc. (NASDAQ - CPXX), which is developing oncology drugs, in transitioning from a venture-financed company to a public company and raising more than $125 million in several rounds of financing from venture capital and other accredited investors since 2005. Celator evolved from technology developed at the British Columbia Cancer Agency and maintains a subsidiary in Vancouver, British Columbia. The Series B round included a completed cross-border restructuring. After subsequent venture financings, we represented Celator in attaining status as a public company through a Form 10 filing, followed by a $39.3 million private placement led by Valence Life Sciences.; Represented Gliknik Inc., a privately held biopharmaceutical company, in negotiating an exclusive worldwide license agreement with Pfizer Inc. for Gliknik's recombitant stradomer GL-2045, a drug candidate designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). Gliknik received an upfront payment of $25 million and is eligible to receive development, regulatory and commercial milestone payments and tiered, double-digit royalties on net sales of any products commercialized under the license agreement.; Represented Tissue Analysis, a wound imaging and telehealth company, in its $750, 000 seed funding round.; Represented Current Analysis, Inc., an IT and telecom market-research firm, in the sale of the company to UK-based Progressive Digital Media Group.; Represented Ceptaris Therapeutics in its acquisition by Actelion for $250 million cash plus undisclosed milestone payments and sales earnouts.; Represented a specialty pharmaceutical company with a focus on the development of novel topical dermatological therapies in connection with its preferred stock financings, totaling $42 million in proceeds.; Represented biopharmaceutical company Ception Therapeutics, Inc. in several transactions, including its $77 million Series C financing and its acquisition by Cephalon, Inc. for $250 million and up to $500 million in milestone payments.; Represented CloudBlue Technologies, an electronics disposition management firm, in its sale to Ingram Micro and its preferred stock financings preceding the sale.; Represented Penrith Corporation, a manufacturer of integrated ultrasound imaging systems, in its financing transactions and its disposition to Siemens Healthcare.; Represented Iroko Holdings S.A. (Luxembourg) in its acquisition of iCeutica Inc. (Australia), a nanotechnology platform company, for an undisclosed amount.; Represented Protez Pharmaceuticals, Inc. in two rounds of Preferred Stock financing from venture capital investors and its acquisition by Novartis Pharmaceuticals Corporation, a structured acquisition with a $100 million up-front payment. Counsel to Protez Pharmaceuticals in venture capital financings and business initiatives for several years prior to its sale.; Represent a medical device company developing adhesive products in its significant commercial contracts with distributors and strategic partners.; Serve as outside general counsel to a service provider to pharmaceutical sponsors and contract research organizations conducting clinical trials in its master services agreements and other commercial arrangements in the U.S., the EU and Asia. Also represented the client in managing its client relationships following an internal reorganization completed to enable its divestiture from the parent company to a private equity investor and operation as an independent business.; Serve as U.S. outside general counsel to an oil services company with operations in Latin America. Also represented the client and led cross-border legal teams in its Preferred Stock financings from Latin American and North American investment/private equity funds, as well as its acquisition transactions within the U.S. and Latin America.; Represented a major French company in connection with a complete reorganization of the worldwide holdings of a significant U.S. subsidiary to enable a $1 billion divestiture and a $650 million divestiture.

Documents by this lawyer on

Subscribe to this feed

SEC Adopts "Regulation A+" Rules
Darrick M. Mix,Howell J. Reeves,Barry Steinman,Sandra G. Stoneman, April 27, 2015
On March 25, 2015, the U.S. Securities and Exchange Commission (SEC) adopted final rules amending Regulation A under the Securities Act of 1933.[1] Regulation A, as amended (which is referred to as "Regulation A+"), is designed to increase access to capital for nonpublic companies and...
Profile Visibility
#1,156 in weekly profile views out of 17,392 lawyers in Philadelphia, Pennsylvania
#110,987 in weekly profile views out of 1,739,582 total lawyers Overall

Office Information

Sandra G. Stoneman

30 South 17th Street
PhiladelphiaPA 19103-7396


Professional Networking for Legal Professionals Only

Quickly and easily expand your professional
network - join the premier global network for legal professionals only. It's powered by the
Martindale-Hubbell database - over 1,000,000 lawyers strong.
Join Now